

REFERENCE NO.

96

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 47/36, A61P 1/04, A61K 31/736		A1	(11) International Publication Number: WO 00/67799
			(43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/GB00/01711			(81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 4 May 2000 (04.05.00)			
(30) Priority Data: 9910212.1 5 May 1999 (05.05.99) GB			
(71) Applicant (for all designated States except US): RECKITT & COLMAN PRODUCTS LIMITED [GB/GB]; 67 Alma Road, Windsor, Berkshire SL4 3HD (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): DETTMAR, Peter, William [GB/GB]; Tithe House, Tithe Barn Lane, Patrington, East Yorkshire HU12 0PE (GB). DICKSON, Paul, Andrew [GB/GB]; 21 Westfield Garth, Walkington, East Yorkshire HU17 8TJ (GB). HAMPSON, Frank, Chadwick [GB/GB]; 93 Inmans Road, Hedon, East Yorkshire HU12 8NQ (GB). JOLLIFFE, Ian, Gordon [GB/GB]; 47 Kingsway, Cottingham, East Yorkshire HU16 5BB (GB).			
(74) Agents: DICKSON, Elizabeth, Anne et al.; Reckitt Benckiser plc, Group Patents Department, Dansom Lane, Hull HU8 7DS (GB).			Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: COMPOSITIONS FOR TREATMENT OF DISORDERS OF THE OESOPHAGUS			
(57) Abstract <p>Pharmaceutical compositions having improved bioadhesive properties are produced by combining an alginate, xanthan gum and/or a carageenan gum and a glucomannan and/or a galactomannan. The composition can provide both a protecting and a healing effect on mucosal surface.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Compositions for treatment of disorders of the
oesophagus

5 The present invention relates to a compositions
capable of detachable adherence to a surface. More
particularly, the present invention relates to such
compositions for use in coating a biological, for
example, mucosal surface and/or delivering an
10 active ingredient to the biological surface.

 Many compositions are known to be bioadhesive
(i.e. able to adhere to biological surfaces, e.g.
mucus, the skin, mucosal surfaces, epithelium etc.)
15 and the value of this property is well recognised.
For example, bioadhesives may be used to adhere
active agents to specific sites in the body for
local drug administration, or to coat particular
parts of the body.

20 However, when bioadhesives are applied to such
surfaces in aqueous solution they may be easily
washed off or mechanically removed because the
strength of adhesion of each individual bioadhesive
25 molecule to the surface is not very high. This may
lead to further problems if the bioadhesive
materials contain active agents intended for use at
one particular site, but which are washed away to
other sites.

30 This is especially true where bioadhesives are
applied to the upper gastrointestinal (GI) tract
where washing off by swallowed saliva and/or mucus
is a particular problem.

35

The prior art does not provide a composition which is able to adhere to biological surfaces and which can provide both physical protection, for example, against episodes of gastric reflux as well as exert a curative effect on the surface, for example, by delivering a pharmaceutically active ingredient to the surface.

A need therefore exists for a bioadhesive pharmaceutical composition which is able to coat a biological surface to protect and heal the surface and/or to deliver an active ingredient to the surface throughout the GI tract.

The need extends to a pharmaceutical composition which is capable of detachably adhering to desired regions of the oesophagus immediately following ingestion and prior to the composition reaching the stomach, the composition being able to exhibit both a protective and a direct healing effect, whether this arises as a result of the barrier properties alone or as a consequence of the incorporation of further active ingredients in the formulation which may have a beneficial effect on the healing process, immediately after ingestion and prior to contact with the stomach.

It is also desirable that the compositions are able to resist washing off by physiological fluids such as saliva or fluids which are subsequently ingested by the user and/or refluxed from the stomach.

In addition to the above, it is important that, when in liquid form, the compositions are of such a viscosity that they are capable of being provided

in and reproducibly dispensed from a single container in a form which is immediately ready for use by the consumer.

5 We have now found a novel composition for detachable adhesion on biological surfaces of mammals which satisfy some or all of the above needs. The viscosity and adhesion of the resulting formulations are such that these compositions show
10 good adhesion, stability and wash-off resistance.

 According to a first aspect of the present invention there is provided a pharmaceutical composition for the treatment of disorders of the
15 oesophagus, the composition comprising:

- a) 0.1 to 11.0 parts by weight, preferably 2.5 to 8 parts by weight alginate (hereinafter component a);
- 20 b) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from xanthan gum, carageenan gum and mixtures thereof (hereinafter component b); and
- 25 c) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from a galactomannan, a glucomannan and mixtures thereof (hereinafter component c).

 The term 'alginate' is intended to encompass
30 alginic acids, salts of alginic acids (alginate salts), derivatives of alginic acid, for example esters such as propylene glycol and mixtures thereof.

The alginate is preferably a monovalent salt of alginic acid, for example the sodium, potassium or ammonium salt, most preferably the sodium salt. Such alginates may be supplied by FMC Biopolymer AS, for example Protanal LFR5/60 and Protanal LF10L.

Preferably, the composition includes 1 to 10 parts by weight of alginate, more preferably between 2 and 9 parts by weight and most preferably between 3 and 8 parts by weight.

Preferably component b) includes a major amount of xanthan gum. Most preferably, component b) consists essentially of xanthan gum.

In the context of this specification, a major amount means that more than 50% by weight, preferably more than 70% by weight, more preferably more than 90% by weight, especially more than 95% by weight of the referenced component is present.

Component c) may be any pharmaceutically acceptable glucomannan or galactomannan, including enzymatically altered derivatives thereof. Preferably, however, component c) includes a major amount of a galactomannan. Preferably, component c) consists essentially of a galactomannan, especially locust bean gum.

Preferably components b) and c) are present in a total amount of from 0.2 to 2.5 parts by weight, more preferably 0.7 to 2 parts by weight, most preferably 1 to 1.6 parts by weight. Preferably components b) and c) are present in amount ratios of from 1:10 to 10:1, most preferably 2:8 to 8:2.

In a preferred embodiment of the present invention, b) is present in an amount greater than c) such that the ratio of b):c) is in the range 1.5:1 to 3.5:1, more preferably in the range 2:1 to 3:1, especially about 2.3:1.

It will be appreciated that the compositions according to the present invention may be presented in solid form, for example as a chewable tablet, in granular or powder form, as a gel or as a liquid. It is preferred however, that the composition is in the form of a liquid, most preferably a pourable liquid.

Pourable means flowable at room temperature (for example, 20-24°C) (possibly following reasonably vigorous shaking) such that doses of, for example, 5ml may be measured out with reasonable accuracy. For example, reproducible doses of as low as 5ml may be dispensed from bottles having neck diameters of 1.5cm or more.

Preferably the composition has a viscosity of between 500 and 10000mPa.s, most preferably between 1000 and 8000 mPa.s measured on a Brookfield Viscometer at 20°C using spindle No. 3.

When in the form of a liquid, it is most preferred that the compositions are aqueous liquids.

In a most preferred embodiment there is therefore provided an aqueous bioadhesive pourable liquid composition for coating a biological surface in the treatment and/or prevention of reflux

oesophagitis, gastritis, dyspepsia and disorders of the oesophagus associated with reflux, the composition comprising:

- 5 a) 0.1 to 11% weight, preferably 2.5 to 8% weight alginate salt (hereinafter component a);
- b) 0.01 to 3.0% weight, preferably 0.1 to 1.5% weight xanthan gum (hereinafter component b); and
- 10 c) 0.01 to 3.0% weight, preferably 0.1 to 1.5% weight galactomannan or glucomannan (hereinafter component c).

Any component described herein as being included in a composition according to the invention may be included in the aqueous composition of the most preferred embodiment. Where an amount is stated in parts by weight in relation to an embodiment, the same numerical value or values expressed as "% weight" may be applied to said most preferred embodiment. Thus, by way of example, it is described above that a composition may include 1 to 10 parts by weight alginate. This may be expressed as 1 to 10% weight when applied to said most preferred formulation and so on.

25 Mixtures of xanthan gum and a glucomannan, or galactomannan for example locust bean gum, have been widely used as thickening and gelling agents in the food industries. However, an aqueous mixture of 1.0% weight xanthan gum and 0.4% weight locust bean gum has a viscosity of approximately 35,000 mPa.s at 20°C measured on a Brookfield Viscometer using spindle No. 3. In effect, this has a jelly like consistency which is disadvantageous in that it is firstly difficult to reproducibly pour metered doses, for example of

5ml, from a bottle and secondly, such a thick product does not enjoy wide consumer acceptance because of mouthfeel, appearance and the like.

5

The inventors have surprisingly found that the addition of certain amounts of alginate to the mixture actually reduces the viscosity of the mixture to within consumer acceptance levels.

10

The composition has been found to exhibit superior bioadhesive properties, particularly on mucosal tissue, such as the oesophagus.

15

In a preferred embodiment of the present invention, the composition is also useful in treating and/or ameliorating the effects of gastric reflux by forming a raft which floats on the stomach contents of a consumer of the product, which raft prevents reflux of the gastric contents into the oesophagus or preceding the gastric contents into the oesophagus during reflux.

20

It will be appreciated that the composition preceding gastric content into the oesophagus during an episode of reflux may be beneficial in that the physical barrier of the composition adhering to or coating the oesophagus because of its superior bioadhesive properties will be recharged during such an episode.

25

In accordance with this preferred embodiment of the present invention the composition further includes any one or more further ingredients selected from the group consisting of

30

35

pharmaceutically acceptable gas forming agents, a source of di or trivalent metal ions, buffering agents, preservatives, sweeteners and flavourants.

5

Preferably the pharmaceutically acceptable gas forming agents are carbon dioxide (CO₂) forming agents, preferably alkali metal bicarbonates, for example, sodium bicarbonate, potassium bicarbonate and/or mixtures thereof. The concentration of
10 alkali metal bicarbonate in the compositions of the invention is preferably 0.1 to 8 parts by weight, more preferably 0.5 to 5 parts by weight, even more preferably 1 to 3 parts by weight and most
15 preferably 1.5 to 3 parts by weight.

Preferably the source of di or trivalent metal ions is suitable for cross-linking the alginate molecules in the composition to form an effective
20 raft in the stomach. These metal ions preferably become available when the compositions reach the stomach but must not be available before then (as the compositions will gel too early). Suitable metal ions are aluminium and, preferably, calcium
25 ions. Most preferably the compositions comprise calcium carbonate.

The compositions of the present invention therefore preferably further comprise from 0.1 to 5
30 parts by weight calcium carbonate, more preferably 0.5 to 3.5 parts by weight calcium carbonate, most preferably 0.75 to 3 parts by weight.

35

Agents for adjusting the pH, i.e. buffering agents, for example, monopotassium phosphate and/or dipotassium phosphate may be included in the composition in an amount of 0.01 to 1 parts by weight.

The compositions of the present invention may further comprise preservatives to prevent contamination and subsequent deterioration by micro-organisms. Examples of suitable preservatives are the esters of para-hydroxybenzoic acid and their salts, which are preferably used in combination. Examples of such esters include methyl, ethyl propyl and butyl para-hydroxybenzoate. Preferred concentrations for the preservatives are 0.01 to 0.5 parts by weight.

The compositions of the present invention may also include colourants, sweeteners (e.g. sodium saccharin) and/or flavourants. Preferably such ingredients are present in an amount of 0.01 to 1 parts by weight.

In the composition according to this embodiment of the present invention, the gums, for example xanthan gum and locust bean gum, act as both bioadhesive agents as well as (very valuably) the suspending agent, thereby enjoying a dual function and avoiding the need for a separate suspending agent, for example, carbomer. Preferably, therefore, the compositions according to the present invention contain no suspending agents other than the gums, for example xanthan gum and locust bean gum.

Carbomer has traditionally been used as a suspending agent in compositions including an alginate for raft formation in the stomach to prevent gastric reflux. Carbomer, in the absence of alginate, is a known bioadhesive but loses this property in the presence of alginate. Xanthan gum and locust bean gum, in contradistinction to carbomer, are suitable suspending agents whilst presenting an improved bioadhesive composition. Xanthan gum and locust bean gum are thus suited to replace carbomer as a suspending agent in compositions of this type.

The compositions of the present invention may also include further ingredients in order to enhance the desired properties of the composition. For example, additives such as simethicone may be added to increase the hydrophobicity of the formulation in order to improve its wash-off resistance.

Xanthan gum is commercially available from Kelco and Rhone Poulenc. Locust bean gum is commercially available from Carob S.A. and Rhone Poulenc.

The composition according to the invention may further include an active ingredient selected from the group consisting of acetaminophen, ibuprofen, naproxen, diclofenac, ketoprofen, choline salicylate, benzydamine, buprenorphine, hydrocortisone, betamethasone; decongestants (e.g. pseudoephedrine, phenylephrine, oxymetazoline, xylometazoline); cough suppressants (e.g. dextromethorphan, codeine, pholcodine); expectorants (e.g. guaiphenesin, n-acetylcysteine,

bromhexine); antiseptics (e.g. triclosan, chloroxylenol, amylmetacresol, hexylresorcinol, dichlorobenzyl alcohol, benzyl alcohol); cardiovascular agents (e.g. glyceryl trinitrate);
5 local anaesthetics (e.g. benzocaine, lignocaine); antacid agents (e.g. calcium carbonate, sodium bicarbonate, magnesium trisilicate, aluminium hydroxide, magaldrate,); antiulcer agents (e.g. carbenoxolone, sucralfate, cimetidine, ranitidine, nizatidine, famotidine, omeprazole, pantoprazole);
10 antihistamines (e.g. loratidine, terfenadine, diphenhydramine, chlorphenhydramine, triprolidine, acrivastine); antinausea agents (e.g. prochlorperazine, sumatriptan); bowel regulatory agents (e.g. diphenoxylate, loperamide, sennosides); antifungal agents (e.g. clotrimazole) and antibiotics (e.g. fusafungine, tyrothricin).

20 Whilst the compositions according to the present invention lend themselves to either targeted delivery or sustained release of such an active ingredient, it will be appreciated that such an ingredient is preferably not included in the composition. However, where an active ingredient
25 is included, the composition may include less than 3 parts by weight, more preferably less than 2 parts by weight, most preferably less than 1 parts by weight of the active ingredient.

30 The present invention represents a completely new approach to the problem of gastric reflux in that the oesophagus may be protectively coated with the composition immediately after ingestion of the composition in order to provide a physical barrier
35 against the acid from gastric reflux. Furthermore, the coating may include ingredients which make the

barrier, in effect, act as a chemical barrier (on account of the inclusion of ingredients which are able to neutralise or deactivate the acid or the pepsin which are responsible for irritation in the oesophagus) as well as a physical barrier.

It will be appreciated that the compositions according to the invention may adhere to other biological surfaces of the mammalian body, for example, the oral cavity, the back of the throat and the underside of the tongue or the stomach.

In a preferred embodiment of the present invention there is provided an aqueous bioadhesive pourable liquid composition comprising:

	Monopotassium phosphate	1.00g
	Dipotassium phosphate	4.00g
	Sodium bicarbonate	16.8g
20	Methyl paraben	4.00g
	Propyl paraben	0.60g
	Sodium saccharin	1.00g
	Xanthan gum	9.80g
	Calcium carbonate	8.00g
25	Locust bean gum	4.20g
	Sodium alginate LFR5/60	50.00g
	Flavour	0.70g
	Deionised water	to 1000ml

The compositions according to the present invention may be presented in containers containing multiple doses for example, bottles containing from 50 to 1000ml of a liquid product. The consumer may then dispense the correct dosage from the container for consumption.

The composition of the present invention may be provided in unit dosage form. Thus, for example, the composition may be presented in solid form as discrete tablets or capsules. Alternatively, the
5 composition may be presented in liquid form as a chewable capsule, optionally including a plurality of compartments each containing a fill volume which together total the desired dosage.

10 Preferably however, the composition is presented in liquid or gel form in sachets. The sachets may vary in volume from 1 to 25ml, preferably 5 to 20ml.

15 According to a further aspect to the present invention, there is provided a method of treating and/or preventing reflux oesophagitis, gastritis, dyspepsia and/or disorders of the oesophagus associated with reflux, which method comprises
20 administration of a pharmaceutically effective amount of a pharmaceutical composition comprising:
a) 0.1 to 11 parts by weight, preferably 2.5 to 8 parts by weight alginate, (hereinafter component a);
25 b) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from xanthan gum, carageenan gum and mixtures thereof (hereinafter component b); and
c) 0.01 to 3.0 parts by weight, preferably 0.1 to
30 1.5 parts by weight of gum selected from a galactomannan, a glucomannan and mixtures thereof (hereinafter component c) to a patient in need thereof.

35

In a preferred embodiment of this aspect to the

present invention there is provided a method of treating and/or preventing reflux oesophagitis, gastritis, dyspepsia and/or disorders of the oesophagus associated with reflux, which method comprises administration of a pharmaceutically effective amount of an aqueous bioadhesive pourable liquid composition comprising:

- a) 0.1 to 11% weight, preferably 2.5 to 8% weight alginate salt (hereinafter component a);
 - b) 0.01 to 3.0% weight, preferably 0.1 to 1.5% weight xanthan gum (hereinafter component b); and
 - c) 0.01 to 3.0% weight, preferably 0.1 to 1.5% weight galactomannan or glucomannan hereinafter component c)
- to a patient in need thereof.

According to a further aspect of the present invention there is provided a use of a composition according to the invention in the preparation of a medicament for the treatment of irritation and/or lesions in the oesophagus, diseases or irritations of the mouth, throat, pharynx and/or stomach and/or other diseases caused by or associated with reflux which treatment comprises administering a pharmaceutically effective amount of the medicament to a patient in need thereof.

According to a further aspect to the present invention there is provided the use of a composition comprising;

- a) 0.1 to 11.0 parts by weight, preferably 2.5 to 8 parts by weight alginate (hereinafter component a);
- b) 0.01 to 3.0 parts by weight, preferably 0.1 to

1.5 parts by weight of gum selected from xanthan gum, carageenan gum and mixtures thereof (hereinafter component b); and

5 c) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from a galactomannan, a glucomannan and mixtures thereof (hereinafter component c)

for coating a biological surface in the treatment and/or prevention of reflux oesophagitis,

10 gastritis, dyspepsia and/or disorders of the oesophagus associated with reflux.

In a preferred embodiment of this aspect to the present invention there is provided the use of

15 an aqueous bioadhesive pourable liquid composition comprising:

- a) 0.1 to 11% weight, preferably 2.5 to 8% weight alginate salt (hereinafter component a);
- b) 0.01 to 3.0% weight, preferably 0.1 to 1.5% weight xanthan gum (hereinafter component b);
- 20 and
- c) 0.01 to 3.0% weight, preferably 0.1 to 1.5% weight galactomannan or glucomannan (hereinafter component c)

25 for coating a biological surface in the treatment and/or prevention of reflux oesophagitis, gastritis, dyspepsia and disorders of the oesophagus associated with reflux.

30 According to a further aspect to the present invention there is provided a composition comprising

- a) 0.1 to 11.0 parts by weight, preferably 2.5 to 8 parts by weight alginate (hereinafter
- 35 component a);
- b) 0.01 to 3.0 parts by weight, preferably 0.1 to

1.5 parts by weight of gum selected from xanthan gum, carageenan gum and mixtures thereof (hereinafter component b); and
c) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from a galactomannan, a glucomannan and mixtures thereof (hereinafter component c)

for use in a method of treatment and/or prevention of reflux oesophagitis, gastritis, dyspepsia and disorders of the oesophagus associated with reflux, which method comprises administering a pharmaceutically effective amount of the composition to a patient in need thereof.

In the preferred embodiments of the invention as described, all references to % weight are to % weight per volume.

Any feature of any aspect of any invention or embodiment described herein may be combined with any feature of any aspect of any other invention or embodiment described herein.

The invention will now be illustrated by the following examples.

Example 1

		mg/10ml
5	Monopotassium phosphate	20.00
	Dipotassium phosphate	40.00
	Sodium bicarbonate	168.00
	Ethyl paraben	20.00
	Sodium butyl paraben	2.22
10	Sodium saccharin	10.00
	Xanthan gum	49.00
	Calcium carbonate	80.00
	Locust bean gum	21.00
	Sodium alginate LFR5/60	300.00
15	Flavour	7.00
	Deionised water	to 10ml

Method of manufacture

- | | | |
|----|----|--|
| 20 | 1. | Add locust bean gum to the water, heat to 40°C and mix. |
| | 2. | Add sodium alginate and mix. |
| | 3. | Add sodium bicarbonate, phosphates, ethyl paraben, sodium butyl paraben and sodium |
| 25 | | saccharin and mix. |
| | 3. | Add xanthan gum and mix. |
| | 4. | Add calcium carbonate and mix |
| | 5. | Add flavour and make up to volume with water and mix. |

Example 2

	Monopotassium phosphate	0.2%
5	Dipotassium phosphate	0.4%
	Sodium bicarbonate	2.67%
	Ethyl paraben	0.2%
	Sodium butyl paraben	0.022%
	Sodium saccharin	0.1%
10	Xanthan gum	0.49%
	Calcium carbonate	1.60%
	Locust bean gum	0.21%
	Sodium alginate LFR5/60	5.00%
	Flavour	0.07%
15	Deionised water	to 100% volume
	(All percentages by weight per volume of the composition.)	

Method of manufacture same as Example 1

20

Example 3

		g/1000ml
	Monopotassium phosphate	2.00
	Dipotassium phosphate	4.00
25	Sodium bicarbonate	16.8
	Ethyl paraben	2.00
	Sodium butyl paraben	0.22
	Sodium saccharin	1.00
	Xanthan gum	9.80
30	Calcium carbonate	8.00
	Locust bean gum	4.20
	Sodium alginate LFR5/60	50.00
	Flavour	0.70
	Deionised water	to 1000ml

Method of manufacture

1. Add phosphates, parabens, saccharin and sodium bicarbonate to a portion of the water and mix.
2. Add the xanthan gum and mix.
3. Add the calcium carbonate and mix.
4. Add the locust bean gum and mix.
5. Add the sodium alginate and mix.
6. Add the flavour, make up to volume and mix.

Example 4

		mg/10ml
	Monopotassium phosphate	20.00
15	Dipotassium phosphate	40.00
	Sodium bicarbonate	168.00
	Ethyl paraben	20.00
	Sodium butyl paraben	2.20
	Sodium saccharin	10.00
20	Xanthan gum	49.00
	Calcium carbonate	80.00
	Locust bean gum	21.00
	Simethicone	100.00
	Sodium alginate LFR5/60	100.00
25	Sodium alginate LF10L	100.00
	Flavour	0.70
	Deionised water	to 10ml

Method of manufacture

1. Add phosphates to the water and mix
2. Add sodium bicarbonate, ethyl paraben, sodium butylparaben and sodium saccharin to (1) and mix.
3. Add xanthan gum to (2) and mix.
4. Add calcium carbonate to (3) and mix

5. Add locust bean gum to (4) and mix.
6. Add simethicone to (5) and mix
7. Dry blend the two sodium alginates and add to (6) and mix
- 5 8. Add flavour and make up to volume with water and mix.

Example 5

		mg/10ml
10	Monopotassium phosphate	20.00
	Dipotassium phosphate	40.00
	Sodium bicarbonate	168.00
	Ethyl paraben	20.00
	Sodium butyl paraben	2.22
15	Sodium saccharin	10.00
	Xanthan gum	49.00
	Calcium carbonate	80.00
	Locust bean gum	21.00
	Sodium alginate LF10L	250.00
20	Flavour	7.00
	Deionised water	to 10ml

Method of manufacture same as Example 3.

25 Example 6

	Monopotassium phosphate	1.00g
	Dipotassium phosphate	4.00g
	Sodium bicarbonate	16.8g
30	Methyl paraben	4.00g
	Propyl paraben	0.60g
	Sodium saccharin	1.00g
	Xanthan gum	9.80g
	Calcium carbonate	8.00g
35	Locust bean gum	4.20g

Sodium alginate LFR5/60	50.00g
Flavour	0.70g
Deionised water	to 1000ml

5 Method of manufacture

1. Add the locust bean gum to a portion of the water and heat to 40°C.
2. To a separate portion of the water add sodium
10 alginate, the phosphates, sodium bicarbonate, parabens and saccharin and mix.
3. To a third portion of the water add xanthan gum and mix.
4. Add (2) to (1) and mix.
- 15 5. Add (3) to (4) and mix.
6. Add calcium carbonate, flavour, make up to volume and mix.

20 Example 7

20 A comparative study of the composition according to a preferred embodiment of the invention with a known liquid gastrointestinal product (Gaviscon Liquid (Registered Trade Mark))
25 is undertaken. The adhesion of the compositions to an artificial surface is determined as an indicator of oesophageal bioadhesion. The products are applied to a length of visking tubing set at an angle to the horizontal in a humid environment.
30 The products are eluted from the tubing with a constant flow of water and the amount of product remaining on the tubing is monitored by weight.

35 At least three replicate experiments are performed with each product and the recorded timings averaged.

The results of the comparative study are set out below.

Time (minutes)	% Adhesion		
	Example 3	Example 5	Gaviscon Liquid (RTM)
2.00	17.00	40.00	10.00
4.00	9.00	15.00	3.00
6.00	8.00	11.00	1.00
8.00	7.00	10.00	0.00
10.00	7.00	9.00	0.00
12.00	6.00	10.00	0.00
14.00	4.00	10.00	0.00
16.00	5.00	7.00	0.00
18.00	4.00	7.00	0.00
20.00	4.00	3.00	0.00
22.00	4.00	3.00	0.00
24.00	3.00	1.00	0.00
26.00	3.00	0.00	0.00
28.00	0.00	0.00	0.00

5 Table 3: Comparative Study of Oesophageal Bioadhesion by
Example 3, Example 5 and Gaviscon Liquid (RTM)

Example 8

10		per tablet:
	1. Alginate H120L	250mg
	2. Xanthan gum	35mg
	3. Locust bean gum	15mg
	4. Xylitol	300mg
15	5. Mannitol	1225mg
	6. Povidone K30	100mg
	7. Flavour	25mg
	8. Magnesium stearate	50mg

Method of manufacture

- 5 1 Dry blend 1, 2, 3, 4 and 5.
2. Granulate using a solution of 6 in isopropanol,
 dry at 50°C.
3. Pass the dried granules through a 1000 micron
 mesh.
- 10 4. Add 7 and 8 to the granules, mix for 3 minutes
 and press into tablets.

Example 9

15

The formulation of Example 3 is packed into foil lined sachets each containing 10 millilitres of the composition. The contents of the sachets may be dispensed by tearing off a portion of the sachet and

20 extruding the contents of the sachet into the mouth.

Example 10

25

Different aqueous mixtures of 1.0% weight/volume xanthan gum and 0.4% weight/volume locust bean gum including different sodium alginate contents were made up and their viscosities measured. The results are set out below.

30

Sodium Alginate (% weight/volume)	Viscosity (measured on a Brookfield Viscometer at 20 °C using spindle 3.) (mPa.s)
0.00	34760.00
2.50	6930.00
5.00	1135.00

7.50	2588.00
10.00	5750.00
12.50	28280.00
15.00	37000.00

Table 1: Viscosity v Sodium Alginate % weight for a 1.0% weight Xanthan Gum and 0.4% weight Locust Bean Gum

5 As can be seen from Table 1 above, sodium alginate concentrations of between 2.5% weight and 10% weight reduce the viscosity of a 1.0% weight xanthan gum and 0.4% weight locust bean gum mixture to below 7000 mPa.s. Such a product is then pourable
10 and enjoys consumer acceptance.

Example 11

15 Using a constant sodium alginate concentration of 5% weight/volume and varying the total xanthan gum and locust bean gum concentration, the following table is obtained.

Total Content Xanthan Gum and Locust Bean Gum (% weight/volume)	Viscosity (measured on a Brookfield Viscometer at 20 °C using spindle 3.) (mPa.s)
0.7	576
1.0	948
1.4	1,135
2.0	2,108

20 Table 2: Viscosity v Total % weight Xanthan Gum and Locust Bean Gum

Table 2 clearly illustrates that particularly acceptable viscosities are achieved with total gum content below 2% weight.

CLAIMS

1. A pharmaceutical composition for the treatment
5 of disorders of the oesophagus, the composition
comprising:
- a) 0.1 to 11.0 parts by weight, preferably 2.5 to
10 8 parts by weight alginate (hereinafter
component a);
- b) 0.01 to 3.0 parts by weight, preferably 0.1 to
1.5 parts by weight of gum selected from
xanthan gum, carageenan gum and mixtures
thereof (hereinafter component b); and
- 15 c) 0.01 to 3.0 parts by weight, preferably 0.1 to
1.5 parts by weight of gum selected from a
galactomannan, a glucomannan and mixtures
thereof (hereinafter component c).
- 20 2. A composition as claimed in claim 1 wherein the
alginate is a monovalent salt, preferably sodium,
potassium or ammonium, most preferably a sodium
salt of alginic acid.
- 25 3. A composition as claimed in either one of
claims 1 and 2 having a viscosity of between 500
and 10000 mPa.s measured on a Brookfield Viscometer
at 20°C using spindle No. 3.
- 30 4. A composition as claimed in any one of claims 1
to 3 in which components b) and c) are present in
total amount of from 0.2 to 2.5 parts by weight,
preferably 0.7 to 2 parts by weight, most
preferably 1 to 1.6 parts by weight.

5. A composition as claimed in any one of claims 1 to 4 wherein components b) and c) are present in amount ratios of from 1:10 to 10:1, preferably 2:8 to 8:2.
- 5 6. A composition as claimed in any one of claims 1 to 5 in which component c) consists essentially of a galactomannan, preferably locust bean gum.
- 10 7. A composition as claimed in any previous claim which contains a source of carbon dioxide, preferably an alkali metal bicarbonate, most preferably sodium bicarbonate and/or potassium bicarbonate.
- 15 8. A composition as claimed in claim 7 which contains a source of di or trivalent cations, preferably calcium ions.
- 20 9. A composition as claimed in any one of the preceding claims further including an active ingredient selected from the group consisting of acetaminophen, ibuprofen, naproxen, diclofenac, ketoprofen, choline salicylate, benzydamine, buprenorphine, hydrocortisone, betamethasone; 25 decongestants (e.g. pseudoephedrine, phenylephrine, oxymetazoline, xylometazoline); cough suppressants (e.g. dextromethorphan, codeine, pholcodine); expectorants (e.g. guaiphenesin, n-acetylcysteine, bromhexine); antiseptics (e.g. triclosan, chloroxylenol, amylmetacresol, hexylresorcinol, dichlorobenzyl alcohol, benzyl alcohol); 30 cardiovascular agents (e.g. glyceryl trinitrate); local anaesthetics (e.g. benzocaine, lignocaine); antacid agents (e.g. calcium carbonate, sodium bicarbonate, magnesium trisilicate, aluminium

hydroxide, magaldrate,); antiulcer agents (e.g. carbenoxolone, sucralfate, cimetidine, ranitidine, nizatidine, famotidine, omeprazole, pantoprazole); antihistamines (e.g. loratidine, terfenadine, 5 diphenhydramine, chlorphenhydramine, triprolidine, acrivastine); antinausea agents (e.g. prochlorperazine, sumatriptan); bowel regulatory agents (e.g. diphenoxylate, loperamide, sennosides); antifungal agents (e.g. clotrimazole) 10 and antibiotics (e.g. fusafungine, tyrothricin).

10. A composition for the treatment of reflux oesophagitis, gastritis, dyspepsia and/or disorders of the oesophagus associated with reflux, the 15 composition comprising:

	Monopotassium phosphate	1.00g
	Dipotassium phosphate	4.00g
	Sodium bicarbonate	16.8g
	Methyl paraben	4.00g
20	Propyl paraben	0.60g
	Sodium saccharin	1.00g
	Xanthan gum	9.80g
	Calcium carbonate	8.00g
	Locust bean gum	4.20g
25	Sodium alginate LFR5/60	50.00g
	Flavour	0.70g
	Deionised water	to 1000ml

11. A composition as claimed in any previous claim 30 presented in unit dosage form, preferably in a sachet.

12. A method of treating and/or preventing reflux oesophagitis, gastritis, dyspepsia and/or disorders 35 of the oesophagus associated with reflux, which

method comprises administration of a pharmaceutically effective amount of a composition comprising:

- 5 a) 0.1 to 11 parts by weight, preferably 2.5 to 8 parts by weight alginate (hereinafter component a);
- 10 b) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from xanthan gum, carageenan gum and mixtures thereof (hereinafter component b); and
- 15 c) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from a galactomannan, a glucomannan and mixtures thereof (hereinafter component c) to a patient in need thereof.

13. Use of a composition as claimed in any one of claims 1 to 11 in the preparation of a medicament for the treatment and/or prevention of irritation and/or lesions in the oesophagus, diseases and/or irritations of the mouth, throat, pharynx and/or stomach and/or other diseases caused by or associated with reflux which treatment comprises administering a pharmaceutically effective amount of the medicament to a patient in need thereof.

14. Use of a composition comprising:
- 30 a) 0.1 to 11.0 parts by weight, preferably 2.5 to 8 parts by weight alginate (hereinafter component a);
 - b) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from xanthan gum, carageenan gum and mixtures thereof (hereinafter component b); and
 - 35 c) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from a

galactomannan, a glucomannan and mixtures thereof (hereinafter component c).

for coating a biological surface in the treatment and/or prevention of reflux oesophagitis, gastritis, dyspepsia and disorders of the oesophagus associated with reflux.

15. A composition comprising

a) 0.1 to 11.0 parts by weight, preferably 2.5 to 8 parts by weight alginate (hereinafter component a);

b) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from xanthan gum, carageenan gum and mixtures thereof (hereinafter component b); and

c) 0.01 to 3.0 parts by weight, preferably 0.1 to 1.5 parts by weight of gum selected from a galactomannan, a glucomannan and mixtures thereof (hereinafter component c)

for use in a method of treatment and/or prevention of reflux oesophagitis, gastritis, dyspepsia and disorders of the oesophagus associated with reflux, which method comprises administering a pharmaceutically effective amount of the composition to a patient in need thereof.

16. An aqueous bioadhesive pourable liquid composition for coating a biological surface in the treatment and/or prevention of reflux oesophagitis, gastritis, dyspepsia and disorders of the oesophagus associated with reflux, the composition comprising:

a) 0.1 to 11% weight, preferably 2.5 to 8% weight alginate salt (hereinafter component a);

- b) 0.01 to 3.0% weight, preferably 0.1 to 1.5%
weight xanthan gum (hereinafter component b);
and
- 5 c) 0.01 to 3.0% weight, preferably 0.1 to 1.5%
weight galactomannan or glucomannan
(hereinafter component c).
17. A pharmaceutical composition according to the
invention, substantially as hereinbefore described
10 or exemplified.
18. A method of treating and/or preventing reflux
oesophagitis, gastritis, dyspepsia and disorders of
the oesophagus associated with reflux according to
15 the invention, substantially as hereinbefore
described or exemplified.
19. Use of a composition according to the
invention, substantially as hereinbefore described
20 or exemplified.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01711

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K47/36 A61P1/04 A61K31/736

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

WPI Data, PAJ, EPO-Internal, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GB 2 324 725 A (RECKITT & COLMAN PRODUCTS LIMITED) 4 November 1998 (1998-11-04) page 24 -page 25; example 4 page 5, line 7 -page 9, line 31 page 14, line 16 -page 19, line 22	1-19
Y	US 4 717 713 A (ZATZ ET AL.) 5 January 1988 (1988-01-05) column 2, line 55 - line 63 column 8; table 4 column 9; table 9	1-19
A	WO 90 14110 A (VILAIN) 29 November 1990 (1990-11-29) claims 1,4,8	1-19

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

28 August 2000

Date of mailing of the international search report

04/09/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Benz, K

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 00/01711

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
GB 2324725	A	04-11-1998	AU 7068098 A	24-11-1998
			CN 1253505 T	17-05-2000
			EP 0979091 A	16-02-2000
			WO 9848814 A	05-11-1998
			ZA 9803707 A	26-02-1999
US 4717713	A	05-01-1988	NONE	
WO 9014110	A	29-11-1990	AU 5561690 A	18-12-1990
			EP 0472575 A	04-03-1992
			JP 4505267 T	17-09-1992